Candel Therapeutics, Inc.

NasdaqGM:CADL Stock Report

Market Cap: US$299.4m

Candel Therapeutics Management

Management criteria checks 4/4

Candel Therapeutics' CEO is Paul-Peter Tak, appointed in Sep 2020, has a tenure of 4.33 years. total yearly compensation is $1.48M, comprised of 45.1% salary and 54.9% bonuses, including company stock and options. directly owns 0.63% of the company’s shares, worth $1.89M. The average tenure of the management team and the board of directors is 2.8 years and 6.2 years respectively.

Key information

Paul-Peter Tak

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage45.1%
CEO tenure4.3yrs
CEO ownership0.6%
Management average tenure2.8yrs
Board average tenure6.2yrs

Recent management updates

Recent updates

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Dec 11

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Jul 01

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Apr 15

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Sep 15

Candel Therapeutics appoints CFO, chief medical officer

Sep 07

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Oct 21

CEO Compensation Analysis

How has Paul-Peter Tak's remuneration changed compared to Candel Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$52m

Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$1mUS$670k

-US$38m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$2mUS$670k

-US$19m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$957kUS$545k

-US$36m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$3mUS$135k

-US$18m

Compensation vs Market: Paul-Peter's total compensation ($USD1.48M) is about average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Paul-Peter's compensation has been consistent with company performance over the past year.

CEO

Paul-Peter Tak (63 yo)

4.3yrs

Tenure

US$1,484,759

Compensation

Dr. Paul-Peter Tak, M.D. PH.D. FMEDSCI, has been Member of Advisory Board at SecondWave Systems, Inc. from March 2024. He serves as President & Chief Executive Officer at Candel Therapeutics, Inc. since Se...

Leadership Team

NamePositionTenureCompensationOwnership
Paul-Peter Tak
President4.3yrsUS$1.48m0.63%
$ 1.9m
Francesca Barone
Chief Scientific Officer2.9yrsUS$706.88k0.25%
$ 751.3k
Charles Schoch
Interim CFO1.8yrsno data0.070%
$ 210.9k
Seshu Tyagarajan
Chief Technical & Development Officer2.8yrsUS$916.02k0.23%
$ 676.7k
Ileen Winick
Chief People Officerno datano datano data
Susan Stewart
Chief Regulatory Officer4.3yrsno datano data
William Nichols
Chief Medical Officer2.3yrsno data0.17%
$ 517.6k

2.8yrs

Average Tenure

55.5yo

Average Age

Experienced Management: CADL's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul-Peter Tak
President4.3yrsUS$1.48m0.63%
$ 1.9m
Joseph Papa
Independent Director2.4yrsUS$58.19k0.12%
$ 350.7k
Edward Benz
Member of Research Advisory Board & Director7.3yrsUS$56.19k0%
$ 0
Paul Manning
Independent Chairman6.2yrsUS$83.19k7.15%
$ 21.4m
Scott Eggener
Member of Scientific Advisory Boardno datano datano data
Adam Kibel
Member of Scientific Advisory Boardno datano datano data
E. Chiocca
Member of Scientific Advisory Boardno datano datano data
Christopher Martell
Independent Director6.2yrsUS$67.19k2.03%
$ 6.1m
Charu Aggarwal
Member of Scientific Advisory Boardno datano datano data
Steven Albelda
Member of Scientific Advisory Boardno datano datano data
Mark Bloomston
Member of Scientific Advisory Boardno datano datano data
Tri Le
Member of Scientific Advisory Boardno datano datano data

6.2yrs

Average Tenure

68yo

Average Age

Experienced Board: CADL's board of directors are considered experienced (6.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 11:45
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Candel Therapeutics, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Evan SeigermanBMO Capital Markets Equity Research
Judah FrommerCredit Suisse
Vernon BernardinoH.C. Wainwright & Co.